InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.775 0.055 (3.01%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,310 Becoming a substantial holder 22 Oct 2026 7:20PM $1.830 $1.775 fallen by 3.01%
$2,310 MSB Reports Increased Revenue and Improved Operating Spend 16 Oct 2026 10:15AM $1.990 $1.775 fallen by 10.80%
$2,310 Notification of cessation of securities - MSB 14 Oct 2026 5:10PM $1.990 $1.775 fallen by 10.80%
$2,310 Notification regarding unquoted securities - MSB 14 Oct 2026 5:07PM $1.990 $1.775 fallen by 10.80%
$2,310 Application for quotation of securities - MSB 14 Oct 2026 5:03PM $1.990 $1.775 fallen by 10.80%
$2,310 Annual Report to Shareholders 12 Oct 2026 4:23PM $2.060 $1.775 fallen by 13.83%
$2,310 Notice of Annual General Meeting and Proxy Form 12 Oct 2026 4:13PM $2.060 $1.775 fallen by 13.83%
$2,310 Appendix 4G and Corporate Governance Statement 12 Oct 2026 4:05PM $2.060 $1.775 fallen by 13.83%
$2,310 Ceasing to be a substantial holder 1 Oct 2026 6:49PM $2.070 $1.775 fallen by 14.25%
$2,310 Becoming a substantial holder 30 Sep 2026 6:15PM $2.110 $1.775 fallen by 15.88%
$2,310 FDA Approves New Potency Assay for Commercial Ryoncil 24 Sep 2026 9:52AM $2.180 $1.775 fallen by 18.58%
$2,310 Ceasing to be a substantial holder 23 Sep 2026 6:41PM $2.180 $1.775 fallen by 18.58%
$2,310 MSB Annual Financial Results and Operational Update 27 Aug 2026 8:39AM $2.360 $1.775 fallen by 24.79%
$2,310 Annual Financial Results Presentation 27 Aug 2026 8:33AM $2.360 $1.775 fallen by 24.79%
$2,310 Preliminary Final Report including Appendix 4E 27 Aug 2026 8:21AM $2.360 $1.775 fallen by 24.79%
$2,310 Appendix 3Y - Philip Krause 24 Aug 2026 5:50PM $2.350 $1.775 fallen by 24.47%
$2,310 Notification regarding unquoted securities - MSB 24 Aug 2026 5:40PM $2.350 $1.775 fallen by 24.47%
$2,310 Mesoblast 2026 Full Year Financial Results Webcast 24 Aug 2026 5:38PM $2.350 $1.775 fallen by 24.47%
$2,310 Major Milestone Treatment Completed in P3 Trial for CLBP 17 Aug 2026 10:00AM $2.200 $1.775 fallen by 19.32%
$2,310 Becoming a substantial holder 13 Aug 2026 5:52PM $2.380 $1.775 fallen by 25.42%
$2,310 Ceasing to be a substantial holder 7 Aug 2026 5:02PM $2.230 $1.775 fallen by 20.40%
$2,310 Becoming a substantial holder 5 Aug 2026 6:29PM $2.130 $1.775 fallen by 16.67%
$2,310 Ceasing to be a substantial holder 3 Aug 2026 5:25PM $2.030 $1.775 fallen by 12.56%
$2,310 Becoming a substantial holder 31 Jul 2026 5:06PM $2.050 $1.775 fallen by 13.41%
$2,310 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2026 10:01AM $2.010 $1.775 fallen by 11.69%

1 - 25 of 1198 results

Page 1 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.